In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.
In this sixth installment, Tanios Bekaii-Saab, MD, and Shubham Pant, MD, discuss the role cost plays in selecting cancer regimens.
In this fifth installment, Shubham Pant, MD, and Tanios Bekaii-Saab, MD, discuss the best practices for treating adverse events associated with treatments such as FOLFIRINOX or NALIRIFOX.
In this first installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss how patients are evaluated for pancreatic cancer.